• Health and Nutrition

Efficacy and resistance to anti-tumour targeted therapies (CANTHER)

Research team - UMR9020 CNRS – UMR1277 Inserm

Description

The overall objective of our team is to decipher the molecular mechanisms leading to oncogenic addiction, then to the process of resistance, in order to improve the effectiveness of targeted therapies. We focus on lung and prostate cancer and their metastatic stage, both of which are the leading cause of cancer mortality. We benefit from our expertise in oncogenes whose involvement in each of these cancers is well documented, including tyrosine kinase activity receptors (RTK) and ETS fusion genes. We are also developing new therapeutic approaches to correct non-sense mutations that account for 5-40% of mutations affecting tumour suppressor genes and are responsible for about 10% of genetic diseases.

Contacts

  • David Tulasne
    Research director

Informations

1, place de Verdun, Bâtiment Cancer
Campus Santé, Université de Lille
59045 LILLE

http://canther.fr/fr/equipe-efficacite-et-resistance-aux-therapies-ciblees-anti-tumorales/

Effectif

Effectif total : 12

Personnel d'appui à la recherche : 4

Expertises

Skills

• Oncogenes
• Targeted therapies
• Resistance to targeted anti-tumor therapies
• Involvement of the tyrosine kinase MET receptor in cancer
• ETS mergers in prostate cancer and metastatic formation
• Bone metastases and HTA transcription factors
• Mechanisms of resistance to targeted therapies and evaluation of innovative therapeutic strategies.
• Non-sense mutations in cancers and other genetic diseases

Example(s) of publications

Our publications can be found here : 🡭

Services offers

Applications sectors

  • Health / wellness
  • Science / Research

Ecosystem

Affiliated institutions / organisations

CHU de Lille
Inserm
University of Lille
CNRS
Centre Oscar Lambret
Institut Pasteur de Lille

Unit(s) of attachment

Regional strategic areas of activity

  • Health and Nutrition
    • New therapeutic approaches

Request for modification

You enter the « edit request » mode. After sending your modifications, they will first be validated by the Plug in labs Ouest team, before appearing on the platform.

Thematics

Current thematics

  • Health and Nutrition
    • New therapeutic approaches
Title

Current content

Efficacy and resistance to anti-tumour targeted therapies
Type

Current content

Research team
Description

Current content

The overall objective of our team is to decipher the molecular mechanisms leading to oncogenic addiction, then to the process of resistance, in order to improve the effectiveness of targeted therapies. We focus on lung and prostate cancer and their metastatic stage, both of which are the leading cause of cancer mortality. We benefit from our expertise in oncogenes whose involvement in each of these cancers is well documented, including tyrosine kinase activity receptors (RTK) and ETS fusion genes. We are also developing new therapeutic approaches to correct non-sense mutations that account for 5-40% of mutations affecting tumour suppressor genes and are responsible for about 10% of genetic diseases.
Contact informations
Contact

Current content

Contact name Email phone number
TULASNE David david.tulasne@ibl.cnrs.fr (+33) 3 20 87 12 57
URL

Current content

http://canther.fr/fr/equipe-efficacite-et-resistance-aux-therapies-ciblees-anti-tumorales/

Address

Current content

1, place de Verdun, Bâtiment Cancer
Campus Santé, Université de Lille
59045 LILLE
Keywords

Current content

Tyrosine kinase receptor, Intracellular signaling, Tumor suppressor genes, apoptosis, transcriptional regulation, cancer, metastases, targeted therapies, resistance.
Our search domains
Skills

Current content

• Oncogenes • Targeted therapies • Resistance to targeted anti-tumor therapies • Involvement of the tyrosine kinase MET receptor in cancer • ETS mergers in prostate cancer and metastatic formation • Bone metastases and HTA transcription factors • Mechanisms of resistance to targeted therapies and evaluation of innovative therapeutic strategies. • Non-sense mutations in cancers and other genetic diseases
Workforce

Current content

Nombre de chercheurs :
Nombre de doctorants :
Nombre de personnel d'appui à la recherche : 4
Effectif total : 12
Example(s) of projects

Current content

Example(s) of publications

Current content

Our publications can be found here : 🡭
Collaborations/Partners/Scientific clients

Current content

Collaborations/Partners/Private Clients

Current content

Services offers
Training offers

Current content

Services offers

Current content

Consulting services

Current content

Equipments
Equipements spécifiques

Current content

Ecosystem
Affiliated institutions / organisations

Current content

  • CHU de Lille
  • Inserm
  • University of Lille
  • CNRS
  • Centre Oscar Lambret
  • Institut Pasteur de Lille
Établissement(s) partenaire(s)

Current content

Unit(s) of attachment

Current content

  • Cancer Heterogeneity, Plasticity and Resistance to Therapies
Groups/Networks/Federations

Current content

Doctoral schools

Current content

Equipex/EquipEx+/ESR

Current content

Competitive cluster

Current content

Regional strategic areas of activity

Current content

  • Health and Nutrition
  • New therapeutic approaches
Personal informations
Back to top